Plasma metabolomic profiling of proliferative diabetic retinopathy

doi:10.3969/j.issn.1006-7795.2020.01.001

Abstract

Abstract: Objective To investigate the plasma "metabolic fingerprints" of proliferative diabetic retinopathy (PDR) and to explore associated pathogenesis. Methods A total of 1 024 patients with type 2 diabetes mellitus were screened. To match clinical parameters between the case and control subjects, patients with PDR (n=21) or those with a duration of diabetes of ≥ 10 years but non-diabetic retinopathy (NDR, n=21) were assigned to the present case-control study. Distinct metabolite profiles of serum were examined using liquid chromatography-mass spectrometry (LC-MS). Results A total of 136 distinct metabolites between PDR and NDR groups were identified. These metabolites mainly included organic compounds (78%), organoheterocyclic compounds (4%), lipids and lipid-like molecules (3%) and others. Altered metabolites were enriched in 30 KEGG pathways. Three of them were significantly enriched (P<0.05), namely, sulfur metabolism, sphingolipid metabolism, cysteine and methionine metabolism. Conclusion We generated a metabolomic profile for extreme eye phenotype between PDR and NDR groups. The impairment in the metabolism of sulfur, sphingolipid, cysteine and methionine were identified as metabolic dysregulation associated with PDR, which might provide insights into potential new pathogenic pathways for diabetic retinopathy.

Key words: type 2 diabetes mellitus, proliferative diabetic retinopathy, metabolomic, liquid chromatography-mass spectrometry (LC-MS)

CLC Number:

R587.2

Zhu Xiaorong, Yang Fangyuan, Lu Jing, Cao Xi, Yang Guangran, Xie Rongrong, Feng Jianping, Yang Jinkui. Plasma metabolomic profiling of proliferative diabetic retinopathy[J]. Journal of Capital Medical University, 2020, 41(1): 1-7.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.01.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I1/1

References

[1] American Diabetes Association. Microvascular complications and foot care:standards of medical care in diabetes-2018[J]. Diabetes Care,2018,41(Suppl 1):S105-S118.
[2] Klein R, Knudtson M D, Lee K E, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy:XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes[J]. Ophthalmology,2008,115(11):1859-1868.
[3] Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA,2013,310(9):948-959.
[4] Chen L, Cheng C Y, Choi H, et al. Plasma metabonomic profiling of diabetic retinopathy[J]. Diabetes, 2016,65(4):1099-1108.
[5] Pirola L, Balcerczyk A, Okabe J,et al. Epigenetic phenomena linked to diabetic complications[J]. Nat Rev Endocrinol,2010,6(12):665-675.
[6] Munipally P K, Agraharm S G, Valavala V K, et al. Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients[J]. Arch Physiol Biochem,2011,117(5):254-258.
[7] Wilkinson CP, Ferris FL, 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology. 2003,110(9):1677-1682.
[8] Wishart D S, Knox C, Guo A C, et al. HMDB:a knowledgebase for the human metabolome[J]. Nucleic Acids Res, 2009,37(Database issue):D603-610.
[9] Dehdashtian E, Mehrzadi S, Yousefi B, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress[J]. Life Sci, 2018,193:20-33.
[10] Lachin J M, Genuth S, Nathan D M. et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited[J]. Diabetes,2008,57(4):995-1001.
[11] Paris L P, Johnson C H, Aguilar E, et al. Global metabolomics reveals metabolic dysregulation in ischemic retinopathy[J]. Metabolomics,2016,12:15.
[12] Barba I, Garcia-Ramirez M, Hernandez C, et al. Metabolic fingerprints of proliferative diabetic retinopathy:an 1H-NMR-based metabonomic approach using vitreous humor[J]. Invest Ophthalmol Vis Sci,2010,51(9):4416-4421.
[13] Soares M S, Oliveira P S, Debom G N, et al. Chronic administration of methionine and/or methionine sulfoxide alters oxidative stress parameters and ALA-D activity in liver and kidney of young rats[J]. Amino Acids, 2017,49(1):129-138.
[14] Cabreiro F, Picot C R, Perichon M, et al. Overexpression of methionine sulfoxide reductases A and B2 protects MOLT-4 cells against zinc-induced oxidative stress[J]. Antioxid Redox Signal, 2009,11(2):215-225.
[15] Sreekumar P G, Kannan R, Yaung J, et al. Protection from oxidative stress by methionine sulfoxide reductases in RPE cells[J]. Biochem Biophys Res Commun,2005,334(1):245-253.